Alkem Labs (Large Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Alkem Laboratories Limited |
|||
|
Price: ₹5,427.50 | ||
| 52 Week Low: ₹4,407.05 52 Week High: ₹6,439.90 |
|||
| Market Capital: 67,013.19 Crore (Largecap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Alkem Labs Share Price Target For 2024
- 1.1.1: Alkem Labs Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Alkem Labs Share Price Target For 2025
- 1.2.1: Alkem Labs Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Alkem Labs Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Alkem Labs Brief Company Overview
- 4: Alkem Labs Financial Performance
- 4.0.1: Is Alkem Labs A Good Buy For Long Term?
To predict the Alkem Labs's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Alkem Labs Share Price Target For 2024
The line chart displays the monthly closing prices of Alkem Labs with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Alkem Labs shares in 2024, see the table below.
Alkem Labs Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 5629.73 (+3.72%) | Fibonacci Extension Level 50.00% |
| 2024 Target 2 | 5571.04 (+2.64%) | Price Action: 11 Nov 2024 Low |
| 2024 Target 1 | 5491.54 (+1.17%) | Price Action: 14 Nov 2024 Low |
| Current Price | 5427.50 | Alkem Labs's share price as of 20 Dec 2024 |
| Stop Loss 1 | 5374.2 (-0.99%) | Price Action: 25 Nov 2024 Low |
| Stop Loss 2 | 5275.82 (-2.80%) | Price Action: Jan 2024 High |
| Stop Loss 3 | 5220.4 (-3.82%) | Price Action: Mar 2024 High |
Short-Term Technical Outlook
Current Technical Position: Alkem Labs is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹5515.89 serves as the nearest technical reference point.
Historical Returns: 3-month: -10.33% | 6-month: +8.83% | 1-year: +5.11%
Alkem Labs Share Price Target For 2025
The line chart displays the monthly closing prices of Alkem Labs with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Alkem Labs shares in 2025, see the table below.
Alkem Labs Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 6920.56 (+27.50%) | Fibonacci Extension Level 123.60% |
| 2025 Target 2 | 6814.3 (+25.55%) | Price Action: Chart |
| 2025 Target 1 | 6746.83 (+24.30%) | Fibonacci Extension Level 64.90% |
| Current Price | 5427.50 | Alkem Labs's share price as of 20 Dec 2024 |
| Stop Loss 1 | 5090.52 (-6.21%) | Price Action: Apr 2024 High |
| Stop Loss 2 | 4977.53 (-8.30%) | Fibonacci Retracement Level 71.80% |
| Stop Loss 3 | 4867.71 (-10.32%) | Price Action: Jul 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Alkem Labs is currently trading at 50.2% of its 52-week range (₹4407.05 - ₹6439.9).
Long-Term Trend Analysis: The stock shows mixed long-term signals, trading near key moving averages.
Long-Term Performance: 1-year: +5.11% | 3-year: +53.91% | 5-year: +182.41%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Alkem Labs Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹5,427.50 | ||
| 2024 | ₹6,145.08 | +13.22% | ₹6,237.26 |
| 2025 | ₹7,778.70 | +26.58% | ₹7,895.38 |
| 2026 | ₹9,187.58 | +18.11% | ₹9,325.39 |
| 2027 | ₹10,783.23 | +17.37% | ₹10,944.98 |
| 2028 | ₹12,737.43 | +18.12% | ₹12,928.49 |
| 2029 | ₹13,707.98 | +7.62% | ₹13,913.60 |
| 2030 | ₹15,461.16 | +12.79% | ₹15,693.08 |
| 2031 | ₹16,764.79 | +8.43% | ₹17,016.26 |
| 2032 | ₹18,417.22 | +9.86% | ₹18,693.48 |
| 2033 | ₹20,636.46 | +12.05% | ₹20,946.01 |
| 2034 | ₹21,270.88 | +3.07% | ₹21,589.94 |
| 2035 | ₹23,143.61 | +8.80% | ₹23,490.76 |
| 2036 | ₹24,342.00 | +5.18% | ₹24,707.13 |
| 2037 | ₹26,051.20 | +7.02% | ₹26,616.64 |
| 2038 | ₹28,535.50 | +9.54% | ₹28,963.53 |
| 2039 | ₹28,198.32 | -1.18% | ₹28,995.69 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Alkem Labs Brief Company Overview
Alkem Laboratories Limited: A Comprehensive Overview Established in 1973 and headquartered in Mumbai, Alkem Laboratories Limited is a renowned pharmaceutical company in India and globally. Key Products and Services: Branded generics Generic drugs Active...
pharmaceutical ingredients Biosimilars Nutraceuticals Diverse Product Range: Alkem Laboratories caters to a wide spectrum of therapeutic areas, including: Anti-infective Dermatology Cardiac Respiratory Gastro-intestinal Central Nervous System Urology Gynaecology Industry Reputation: Alkem Laboratories has established a strong reputation in the industry for its quality products and commitment to innovation.Alkem Labs Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 67,013.19 Crore | Market valuation of Alkem Labs's shares. |
| Revenue (TTM) | 12,731.68 Crore | Total revenue generated by Alkem Labs over the past twelve months. |
| Net Income (TTM) | +20,541,999,104.00 | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +17.42% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +16.13% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+2.19% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+90.10% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
13.23 | Company's total debt divided by total shareholder equity. |
| Total Debt | 1,418.4 Crore | Sum of Alkem Labs's current & long-term financial obligations. |
| Total Cash | 4,269.71 Crore | Total amount of liquid funds available to Alkem Labs. |
| Beta | 0.41 | Beta is less than 1 indicating that the Alkem Labs's price is less volatile than the market. |
Is Alkem Labs A Good Buy For Long Term?
Alkem Labs, a large-cap stock with a market capitalization of ₹67,013.19 crore, shows strong performance. Its ₹2,054.19 crore net profit (16.13% margin) on ₹12,731.68 crore revenue in the last 12 months, coupled with significant growth (90.1% YoY earnings increase), suggests robust profitability. While debt exists (₹1,418.4 crore), substantial cash reserves (₹4,269.71 crore) mitigate concerns. Past performance (50.46% return in the last 12 months, 187.29% over 5 years) is impressive, indicating potential for long-term growth. Considering this data, Alkem Labs is a good buy for long-term investors.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
